Compare ASML Holding NV (ASML) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASML Holding NV vs GSK plc — how do they compare? ASML Holding NV trades at $1,816 (market cap $689.17B), while GSK plc trades at $50.39 (market cap $102.60B). The key difference: ASML Holding NV is far larger — about 6.7× GSK plc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| ASML | GSK | |
|---|---|---|
Market Cap | $689.17B | $102.60B |
Sector | Technology | Health |
52-Week High | $1.99K | $61.18 |
52-Week Low | $725.85 | $38.22 |
Enterprise Value | $682.70B | $123.04B |
Dividend Yield | 0.5% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASML trades at $1,733.48, down 0.43% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a 29.41% net income margin and robust revenue growth to $32.67B in 2025. Recent earnings beats in Q1 and Q2 2026, coupled with a consensus price target of $2,390, highlight positive momentum, though high valuation ratios like a P/E of 61.28 pose risks.
Outlook remains favorable due to AI-driven semiconductor demand, but investors face risks from geopolitical tensions with China and stretched valuations. Analyst consensus is strongly bullish with 57% buy ratings, supporting potential upside, though monitoring competitive threats and earnings consistency is crucial for sustained growth.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
